Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)4.06
  • Today's Change-0.158 / -3.74%
  • Shares traded167.22k
  • 1 Year change-16.33%
  • Beta1.2139
Data delayed at least 15 minutes, as of Jun 17 2024 16:35 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

  • Revenue in EUR (TTM)30.06m
  • Net income in EUR-39.70m
  • Incorporated2003
  • Employees102.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Maat Pharma SA2.23m-19.72m100.06m50.00--4.09--44.91-1.73-1.730.1961.760.05084.844.1644,560.00-44.99-35.49-58.93-42.9874.28---884.96-1,157.542.76-49.610.4075--55.80---43.78--30.30--
Adocia SA2.15m-21.16m108.57m78.00------50.50-1.93-1.930.194-0.49080.07742.627.4427,564.10-76.16-43.08-396.14-72.937.91---984.28-514.531.01-2.072.12---81.22-46.13-206.65---27.60--
Transgene SA7.63m-22.33m109.51m158.00--6.96--14.34-0.2227-0.22270.07590.15530.1368--4.2848,316.46-40.00-24.81-50.27-29.79-----292.48-193.24----0.4764---23.681.5131.94--14.44--
Eurofins-Cerep SA44.07m7.64m111.98m228.0014.661.7311.652.541,514.431,514.438,743.9412,820.370.58641.675.08193,287.1010.1614.2112.2217.5185.0173.6117.3319.774.87--0.00005---7.4711.60-33.7214.64----
Ose Immunotherapeutics SA2.23m-23.00m136.92m62.00--5.91--61.48-1.18-1.180.11661.060.0256--3.22---26.46-17.17-33.15-20.55-----1,032.87-94.71---97.810.6659---87.83-38.07-29.52---17.11--
Cellectis SA11.34m-73.29m140.37m235.00--1.66--12.38-1.24-1.050.16631.180.04--1.4148,248.19-27.82-24.08-42.40-30.69---64.64-694.72-308.24----0.552---64.26-15.57-20.55---26.15--
Inventiva SA17.48m-110.43m145.36m112.00------8.32-2.45-2.450.3854-0.61460.1884--9.18156,044.60-116.84-54.30-207.08-69.98-----620.31-669.970.9524-19.986.96--43.5040.46-103.46---0.33--
Eurobio Scientific SA130.00m4.84m150.04m137.0033.930.91378.351.150.43150.431511.5916.020.40183.194.31948,927.001.4916.911.8021.5347.1150.953.7223.342.324.030.36660.00-14.8120.80-80.61--20.02--
Aelis Farma SA9.05m-5.08m171.03m26.00--12.96--18.89-0.3907-0.39070.70190.99570.2765--2.41348,230.80-15.51-24.53-25.59-40.55-----56.09-109.622.47--0.1547--137.70--64.46--37.35--
Innate Pharma SA51.90m-7.57m171.83m179.00--3.31--3.31-0.0939-0.09390.64510.6420.2648--5.67289,949.70-3.86-8.83-4.87-12.1194.5093.17-14.59-55.55----0.6408--4.68-8.2786.94--10.50--
Sensorion SA0.00-22.06m198.17m50.00--3.71-----0.2063-0.20630.000.17790.00-------51.64-35.12-71.66-46.97------------0.0794------4.94--126.45--
Nanobiotix SA30.06m-39.70m198.90m102.00------6.62-1.10-1.100.814-0.03910.3912--19.59294,686.30-51.67-54.11-120.56-80.68-----132.08-756.15---1.981.04----203.8830.40---7.81--
Genfit SA38.18m-28.89m199.95m159.00--2.94--5.24-0.5814-0.58140.76811.360.1961542.003.52240,100.60-14.84-12.57-18.55-15.3094.3294.96-75.69-76.232.94-7.780.5080--43.7038.49-21.82---3.27--
Euroapi SA1.02bn-189.70m277.21m3.67k--0.2965--0.2721-2.01-2.0110.739.780.60861.384.24277,705.10-11.34---15.93--16.15---18.63--0.6573--0.1955--3.87---1,164.67------
Data as of Jun 17 2024. Currency figures normalised to Nanobiotix SA's reporting currency: Euro EUR

Institutional shareholders

9.26%Per cent of shares held by top holders
HolderShares% Held
Invus Public Equities Advisors LLCas of 24 Apr 20243.07m6.51%
Baillie Gifford & Co.as of 07 Sep 2023488.43k1.04%
G�n�rali Investments Partners SpA SGR (France)as of 30 Dec 2022187.50k0.40%
Financi�re Arbevel SAas of 30 Dec 2022148.19k0.31%
SG 29 Haussmann SASUas of 11 Jun 2024110.00k0.23%
OFI Invest Asset Management SAas of 27 Mar 202488.33k0.19%
SSgA Funds Management, Inc.as of 06 Jun 202485.28k0.18%
Talence Gestion SASas of 30 Apr 202477.00k0.16%
Medical Strategy GmbHas of 29 Feb 202461.08k0.13%
BG Fund Management Luxembourg SAas of 31 Dec 202350.49k0.11%
More ▼
Data from 29 Feb 2024 - 13 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.